Mitochondria-targeted hydroxyurea inhibits OXPHOS and induces antiproliferative and immunomodulatory effects

Summary: Hydroxyurea (HU), an FDA-approved drug for treating sickle cell disease, is used as an antitumor drug alone and together with conventional chemotherapeutics or radiation therapy. HU is used primarily to treat myeloproliferative diseases because it inhibits the enzyme ribonucleotide reductas...

Full description

Bibliographic Details

Published in:	iScience
Main Authors:	Gang Cheng, Micael Hardy, Paytsar Topchyan, Ryan Zander, Peter Volberding, Weiguo Cui, Balaraman Kalyanaraman
Format:	Article
Language:	English
Published:	Elsevier 2021-06-01
Subjects:	Drugs Organic chemistry Biological sciences Immunology
Online Access:	http://www.sciencedirect.com/science/article/pii/S2589004221006416